Please use this identifier to cite or link to this item:
Title: Clinical behavior of small cell lung cancer
Authors: Ventura, Sara Manso 
Orientador: Carvalho, Lina
Pêgo, Alice Mariano
Keywords: Carcinoma de pequenas celulas; Pulmão
Issue Date: 2009
Abstract: Introduction: Lung Cancer is the leading cause of cancer death in the United States and Western Europe. Small cell lung cancer (SCLC) accounts for up to 13% of all newly diagnosed lung cancers. The knowledge of factors that could predict the clinical outcome of patients with SCLC is important for guiding treatment and to determining prognosis. Imunohistochemical study by the analysis and characterization of markers involved in SCLC could improve the knowledge of prognostic factors. The purpose of this article is to investigate the prognostic value of six Imunohistochemical Markers in patients with SCLC diagnosis: Chromogranin A (Chromo A), Cytokeratin 7 (CK7), Thyroid transcription factor-1 (TTF-1), Neural cell adhesion molecule/CD56, Ki-67 (MIB1) and High weight cytokeratin (LP34). Material and Methods: Patients had a histological confirmed small-cell lung cancer (SCLC) diagnosed at our University Hospital between February 2002 and December of 2008 and a total of 100 cases (13 women, 87 men) were selected for this study. Results: The mean survival of all patients was 274 days (9months), and median was 183 days (6months). The survival mean for LD-SCLC was 482 days (16months, with a 95% Confidence Interval from 10 months to 22 months) and 182 days for ED-SCLC (6months, with a 95% Confidence Interval from 4 months to 8 months). The patients showed a significant meaning in Chromo A curves isolated, with a mean of Survival with the group expressing A of 6,7 months and 11 months in the group 3 expressing B. Tumors that expressed Chromo A (B) & CD56 (A) had the best prognosis with a survival mean of 726 days (24,2months) against 234 days (7,8 months). The worst prognosis was for the combination of CD56 (B) + Ki67 (B) with a survival mean of 6 months against 11 months for the rest of the patients. Conclusion: Based on those considerations, we hypothesize that Chromo A isolated could be a prognostic factor of survival. Patients that show Chromo A (B) & CD56 (A) had a very good prognosis with a mean of survival of 726 days. On other hand, patients that show CD56 (B) + Ki67 (B) had a poor prognosis with a mean of survival of 6 months
Description: Trabalho de mestrado integrado em Medicina (Pneumologia), apresentado á Faculdade de Medicina da Universidade de Coimbra
Rights: openAccess
Appears in Collections:UC - Dissertações de Mestrado
FMUC Medicina - Teses de Mestrado

Files in This Item:
File Description SizeFormat
Article.pdf366.2 kBAdobe PDFView/Open
Show full item record

Page view(s) 5

checked on Feb 20, 2024


checked on Feb 20, 2024

Google ScholarTM


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.